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643Abstracts
United States hospitals included in the ADHERE patient registry.
All beneﬁts were assumed to accrue in the index hospitalisation
and treatment-speciﬁc lengths of stay were estimated after
adjusting for prognostic indicators. A constant factor was used
to adjust US LOS estimates to reﬂect Swiss patterns. Age-speciﬁc
all-cause mortality at six months was derived from the literature.
Treatment costs are reported in 2003 Swiss francs (CHF) and
include: hospital per diems (from a sample of university hospi-
tals, and including physician costs) and medications for heart
failure. The base-case was estimated for patients aged 75 years
with moderate left ventricular dysfunction (ejection fraction
35–44%). RESULTS: For 1000 subjects admitted with ADHF,
the number of subjects surviving at six month was estimated to
be: 837 for initial treatment with nesiritide, 826 for dobutamine,
and 833 for milrinone. The total cost of treating these cohorts
is estimated at CHF 9.0 million for nesiritide, CHF 10.2 million
for dobutamine, and CHF 11.9 million for milrinone. CON-
CLUSIONS: Based on available data, the base-case shows that
nesiritide is at least as effective as inotrope therapy at reducing
mortality in persons admitted to hospital for ADHF. While the
acquisition cost of nesiritide is higher than that for the inotropes
nesiritide is less costly than inotropic therapy at six months in
Swiss university hospitals.
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OBJECTIVES: After 1990, it was recognised that the male pop-
ulation’s life expectancy increased relatively quickly. This elon-
gation was signiﬁcant in decreasing the mortality rate from
diseases of the circulatory system, mainly ischemic heart diseases.
METHODS: Regression cost analysis was used for analysis of
databases such as OECD Health Data, The Ministry of Health
and Statistic institution of the Czech Republic. RESULTS: From
the analysis it is evident that decreasing the concentration of cho-
lesterol in blood plasma of the Czech population (mainly HDL
cholesterol), an exponential increase in the number of people
undergoing cardio surgery and consumption of modern effective
drugs have all had positive effects. Use of antihypertensives in
the years 1994–2003 has increased by more than ten times.
Moreover, use of serum lipid reducing agents has increased sig-
niﬁcantly by more than 15 times since 1995. In 2002 pharma-
ceutical expenditures totaled 48,032 billion Czech crowns (1501
billion €). Use per inhabitant was 4681 Czech crowns (151€).
Cardiovascular drug use was 19.6% of total volume of drugs in
the year 2002. To save one year life in the general population
aged 0–69 years as a result decreasing mortality of ischemic heart
disease, marginal costs for drugs for cardiovascular diseases was
185,000 Czech crowns (5968€). CONCLUSIONS: Drugs for the
treatment of the circulatory system play a signiﬁcant role in drug
policy. The rate of reimbursement drugs from public resources
remains controversial and problems regarding drug policy in the
Czech Republic have not yet been resolved.
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OBJECTIVES: Patients with advanced nonsmall cell lung cancer
have been treated more intensively over the past decade. We
sought to see how changes in treatment intensity inﬂuenced sur-
vival and costs over time. METHODS: Patients ages 65+ diag-
nosed with early stage primary lung cancer were identiﬁed from
the SEER-Medicare database, a national clinical cancer registry
linked to Medicare claims ﬁles. Individuals were included if they
were diagnosed with locally advanced or metastatic (TNM stages
IIIb and IV) NSCLC between January 1, 1994 and December 31,
2001. Kaplan-Meier survival curves were ﬁtted for cohorts diag-
nosed each year from 1994 to 1999. Lifetime medical costs were
calculated for each chemotherapy group using the Kaplan Meier
sample average estimator. To determine whether there was a
trend in costs over time, a regression model was ﬁtted to lifetime
cost estimates for each successive cohort. RESULTS: A total of
14,875 patients met inclusion criteria (approximately 2300 per
year): 7411 (49.8%) stage IIIb and 7464 (50.2%) stage VI at
diagnosis. Proportion of patients receiving procedures in the ﬁrst
three months from diagnosis in 1994 and 1999 were as follows:
no procedure: 38%, 31%; surgery: nine percent (9%), seven
percent (7%), radiation therapy: 47%, 48%; chemotherapy:
27%, 43%. Survival for patients diagnosed in 1994 was 24% at
12 months and 11% at 24 months. Survival for those diagnosed
in 1999 was 27% at 12 and 12% at 24 months (log rank test
for equality, p = 0.57). In constant dollars, lifetime costs per
patient increased from $26,000 to $42,000 over this time period
(OLS regression for time trend: p < 0.002). CONCLUSIONS:
Costs of care for patients with advanced NSCLC diagnosed
between 1994 and 1999 increased 62% with no change in sur-
vival over this time period. Chemotherapy use accounted for the
majority of the increases in treatment intensity and cost.
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OBJECTIVES: Aim of this study was to evaluate cost-
effectiveness of rituximab + CHOP (R-CHOP) versus CHOP, in
patients affected by aggressive Non-Hodgkin lymphoma, in the
Italian NHS’ perspective. METHODS: The economic analysis is
based on an existing Markov model which was developed in
order to evaluate costs and effects for two hypotetical cohorts of
patients of age respectively higher and lower than 60 years, over
a time frame of 15 years after administration of chemotherapy.
The model is based on 5 health states (start therapy, complete
response, no response, progression, death) and combines efﬁcacy
data from published clinical trials (GELA-98-5) with utilities
from the literature and cost of therapies and medical follow-up
after chemotherapy, based on Italian treatment patterns. Costs
and effects were discounted respectively at 6% and 1,5%. Exten-
sive 1-way and Monte Carlo sensitivity analyses were conducted
in order to test the robustness of results. RESULTS: For the 2
cohorts (60+; 60-), incremental discounted Life Years Gained
with R-CHOP versus CHOP were respectively 1.08 and 1.02
years; incremental QALYs were 1.15 and 1.04; the incremental
cost/patient was 14.838€ and 13.938€; the incremental cost/LYG
was therefore 13.732€ and 13.717€ and the incremental
cost/QALY was 12.879€ and 13.362€, respectively for 60+ and
60- patients. CONCLUSIONS: The clinical advantage of R-
CHOP is supported by incremental cost/LYG and cost/QALY
ratios which fall well below all the thresholds commonly indi-
cated for these values both in the international and italian liter-
ature. R-CHOP is a substantial improvement in the treatment of
